PepGen (NASDAQ:PEPG) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of PepGen (NASDAQ:PEPG) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued research reports about the company. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Craig Hallum began coverage on PepGen in a report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.40.

PepGen Stock Performance

NASDAQ:PEPG opened at $2.62 on Friday. The stock’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $2.23. The company has a market cap of $181.46 million, a P/E ratio of -2.00 and a beta of 2.01. PepGen has a 52-week low of $1.31 and a 52-week high of $7.80.

PepGen (NASDAQ:PEPG) last released its earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, equities analysts predict that PepGen will post -1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PepGen

A number of hedge funds and other institutional investors have recently bought and sold shares of PEPG. Rangeley Capital LLC lifted its stake in shares of PepGen by 88.1% during the 1st quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock worth $121,000 after buying an additional 31,896 shares during the last quarter. Group One Trading LLC bought a new position in PepGen in the 1st quarter valued at about $77,000. Seven Fleet Capital Management LP bought a new position in PepGen in the 1st quarter valued at about $105,000. Dimensional Fund Advisors LP lifted its position in PepGen by 60.4% during the first quarter. Dimensional Fund Advisors LP now owns 216,824 shares of the company’s stock worth $394,000 after acquiring an additional 81,608 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in PepGen during the second quarter worth approximately $171,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins.

PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues.